Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2005; 40(4): 199-206
DOI: 10.1055/s-2004-826116
Aktuelle Medizin und Forschung
© Georg Thieme Verlag KG Stuttgart · New York

Extrakorporale Blutreinigung im schweren Leberversagen mit der Albumindialyse MARS® - Einfluss auf intensivmedizinisch relevante Parameter

Extracorporeal Blood Purification in Severe Liver Failure with the Albumin Dialysis MARS® - Impact on Relevant Intensive Care ParametersS.  Mitzner1 , S.  Klammt1 , J.  Stange1 , G.  F. E.  Nöldge-Schomburg2 , R.  Schmidt1
  • 1 Klinik und Poliklinik für Innere Medizin (Direktor: Prof. Dr. med. habil. R. Schmidt), Universität Rostock
  • 2 Klinik und Poliklinik für Anästhesiologie und Intensivmedizin (Direktorin: Prof. Dr. med. habil. G. F. E. Nöldge-Schomburg), Universität Rostock
Further Information

Publication History

Publication Date:
15 April 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Klinische Studien zum Einsatz von extrakorporalen Leberersatzverfahren werden seit über 50 Jahren durchgeführt. Dabei kamen sowohl die Standard-Blutreinigungstechniken wie die Dialyse, Adsorption, Hämo- und Plasmafiltration als auch Bioreaktor-basierte Ansätze unter Verwendung von Leberzellen oder -geweben zum Einsatz. Die klinischen Erfahrungen beschränken sich dabei allerdings meist auf die Nutzung im akuten Leberversagen. Seit 1993 steht mit dem Molecular Adsorbent Recirculating System (MARS®) ein Verfahren zur Verfügung, das die Techniken von Dialyse, Filtration und Adsorption in einem biokompatiblen Ansatz vereint. Humanes Serum Albumin (HSA) wird dabei als selektiver molekularer Adsorber eingesetzt, der gezielt eiweißgebundene Substanzen, wie etwa Gallensäuren oder Bilirubin, binden kann. Die Anhäufung von Substanzen dieser Gruppe kann wesentlich zum Unterhalt und zur Verstärkung von Organdysfunktionen im Leberversagen beitragen. Sie werden unter anderem mit der Entstehung bzw. Verschlechterung der hyperdynamen hypotonen Kreislaufdysregulation, der hepatischen Enzephalopathie, dem hepatorenalen Syndrom, eingeschränkter hepatischer Proteinsynthese und starkem Juckreiz beim Leberversagen in Zusammenhang gebracht. Das HSA übernimmt die Giftstoffe vom Patientenblut und durchläuft eine, räumlich vom Blut getrennte, Entgiftungsstrecke (eine Bicarbonatdialyse, zwei Adsorber), um dann erneut zum Patientenblut zurückzufließen. Bis heute wurden über 4000 Patienten mit Leberversagen mit mehr als 16 000 Einzelbehandlungen therapiert. Damit handelt es sich beim MARS®-Verfahren um das am häufigsten klinisch eingesetzte Leberunterstützungssystem. Neben akuten Leberversagen wurden vor allem akut dekompensierte chronische Lebererkrankungen (Acute-on-Chronic Liver Failure, ACLF) behandelt. Der Einfluss auf intensivmedizinisch relevante Parameter durch die extrakorporale Behandlung wird im Zusammenhang mit den Besonderheiten eines Patienten mit einem Leberversagen (Infektanfälligkeit, atypischer Infektverlauf, Gerinnungsstörungen mit Blutungsneigung) diskutiert.

Abstract

Extracorporeal liver support methods have been tested for over 50 years now. Standard techniques of blood purification like dialysis, adsorption, hemo- and plasmafiltration as well as bioreactor-based approaches using liver cells or tissues have been used. Most clinical experience, however, is limited to use in acute liver failure (ALF). Since 1993, the Molecular Adsorbent Recirculating System (MARS®) has been used clinically - a system that combines dialysis, filtration and adsorption in a biocompatible method. Human serum albumin (HSA) acts as a selective molecular adsorbent binding protein-bound compounds like bile acids or bilirubin. These substances can contribute to the maintenance or even further aggravation of liver failure. They are linked with the pathogenesis of hyperdynamic hypotonic circulation, hepatic encephalopathy, hepatorenal syndrome, impaired hepatic protein synthesis, and intractable pruritus seen in chronic liver failure. HSA takes over the toxic substances from a patient"s blood and passes through a remote detoxification process including bicarbonate-dialysis and a two-step adsorption. It is then recirculated in the patient's blood. Up to today, more than 4000 patients have been treated in approximately 16 000 single sessions. Thus, MARS® represents the most frequently used liver support method at the present time. In addition to ALF, mainly acute decompensations of chronic liver failures (ACLF) have been treated. The impact of the extracorporeal treatment on relevant medical parameters of intensive care medicine is discussed with regard to the specific situation of the liver-failure patient (susceptibility to infection, atypical picture and course of infection, coagulation disorders and bleeding tendencies).

Schlüsselwörter

Leberschaden · Bilirubin · Gallensäuren · Albumin · Albumindialyse · Leberersatzverfahren

Key words

Hepatic failure · bilirubin · bile acids · albumin · albumin dialysis · liver support methods

Literatur

  • 1 Allen J W, Hassanein T, Bhatia S N. Advances in bioartificial liver devices.  Hepatology. 2001;  34 447-455
    CrossrefPubMedGoogle Scholar
  • 2 Awad S S, Sawada S, Soldes O S, Rich P B, Klein R, Alarcon W H, Wang S C, Bartlett R H. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?.  ASAIO J. 1999;  45 47-49
    PubMedGoogle Scholar
  • 3 Awad S S, Swaniker F, Magee J, Punch J, Bartlett R H. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis.  Surgery. 2001;  130 354-362
    CrossrefPubMedGoogle Scholar
  • 4 Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. Role of MARS in patients suffering from hypoxic liver failure following cardiogenic shock after cardiac surgery (Abstract).  J Hepatol. 2003;  38 (Suppl 2) 35
    PubMedGoogle Scholar
  • 5 Campli C D, Gaspari R, Mignani V, Stifano G, Santoliquido A, Verme L Z, Proietti R, Pola P, Silveri N G, Gasbarrini G, Gasbarrini A. Successful MARS treatment in severe cholestatic patients with acute on chronic liver failure.  Artif Organs. 2003;  27 565-569
    CrossrefPubMedGoogle Scholar
  • 6 Catalina M V, Barrio J, Anaya F, Salcedo M, Rincon D, Clemente G, Banares R. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure.  Liver Internat. 2003;  23 (Suppl 3) 39-43
    PubMedGoogle Scholar
  • 7 Chen S, Zhang L, Shi Y, Yang X, Wang M. Molecular adsorbent recirculating system: clinical experience in patients with liver failure based on hepatitis B in China.  Liver. 2002;  22 (Suppl 2) 48-51
    PubMedGoogle Scholar
  • 8 Covic A, Goldsmith D J, Gusbeth-Tatomir P, Volovat C, Dimitriu A G, Cristogel F, Bizo A. Successful use of Molecular Adsorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion.  Liver Internat. 2003;  23 (Suppl 3) 21-27
    PubMedGoogle Scholar
  • 9 Davenport S. Artificial hepatic support: where are we now?.  Blood Purif. 2001;  19 1-3
    CrossrefPubMedGoogle Scholar
  • 10 Doria C, Mandala L, Smith J, Vitale C H, Lauro A, Gruttadauria S, Marino I R, Foglieni C S, Magnone M, Scott V L. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus.  Liver Transpl. 2003;  9 437-443
    CrossrefPubMedGoogle Scholar
  • 11 Guo L M, Liu J Y, Xu D Z, Li B S, Han H, Wang L H, Zhang W Y, Lu L H, Guo X, Sun F X, Zhang H Y, Liu X D, Zhang J P, Yao Y, He Z P, Wang M M. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.  Liver Internat. 2003;  23 (Suppl 3) 16-20
    PubMedGoogle Scholar
  • 12 Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs.  Liver Internat. 2003;  23 (Suppl 3) 61-65
    PubMedGoogle Scholar
  • 13 Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.  Hepatology. 2002;  36 949-958
    CrossrefPubMedGoogle Scholar
  • 14 Hessel F P, Mitzner S R, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease.  Liver Internat. 2003;  23 Suppl 3 66-72
    PubMedGoogle Scholar
  • 15 Hommann M, Kasakow L B, Geoghegan J, Kornberg A, Schotte U, Fuchs D, Hermann J, Zintl F, Scheele J. Application of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month-old child. Pediatr.  Tranplant. 2002;  6 340-343
    PubMedGoogle Scholar
  • 16 Huster D, Schubert C, Berr F, Mossner J, Caca K. Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS).  J Hepatol. 2002;  37 413-414
    CrossrefPubMedGoogle Scholar
  • 17 Ichai P, Samuel D. Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis?.  J Hepatol. 2003;  38 104-106
    PubMedGoogle Scholar
  • 18 Isoniemi H. Current indications for albumin dialysis: Acute hepatic failure. 4th International Symposium on Albumin Dialysis in Liver Disease, 6. - 8. September 2002, Book of Abstracts. Rostock; 2002 21
    Google Scholar
  • 19 Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis.  J Hepatol. 2003;  38 24-31
    PubMedGoogle Scholar
  • 20 Javouhey E, Collard L, Cochat P, Floret D. Bridge to liver transplantation using extracorporeal albumin dialysis: preliminary results in children (Abstract).  Pediatr Transplant. 2003;  7 (Suppl 4) 121
    PubMedGoogle Scholar
  • 21 Kamath P S, Wiesner R H, Malinchoc M, Kremers W, Therneau T M, Kosberg C L, D'Amico G, Dickson E R, Kim W R. A model to predict survival in patients with end-stage liver disease.  Hepatology. 2001;  33 464-470
    CrossrefPubMedGoogle Scholar
  • 22 Kiley J E, Welch H F, Pender J C, Welch C S. Removal of blood ammonia by hemodialysis.  Proc Soc Exp Biol Med. 1956;  91 489-490
    PubMedGoogle Scholar
  • 23 Kjaergard L L, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review.  JAMA. 2003;  289 217-222
    CrossrefPubMedGoogle Scholar
  • 24 Klammt S, Stange J, Mitzner S R, Peszynski P, Peters E, Liebe S. Extracorporeal liver support by recirculating albumin dialysis: analysing the effect of the first clinically used generation of the MARSystem.  Liver. 2002;  22 (Suppl 2) 30-34
    PubMedGoogle Scholar
  • 25 Koivusalo A M, Yildirim Y, Vakkuri A, Lindgren L, Hockerstedt K, Isoniemi H. Experience with albumin dialysis in five patients with severe overdoses of paracetamol.  Acta Anaesthesiol Scand. 2003;  47 1145-1150
    CrossrefPubMedGoogle Scholar
  • 26 Kramer L, Gendo A, Madl C, Ferrara I, Funk G, Schenk P, Sunder-Plassmann G, Hörl W H. Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy.  Am J Kidney Dis. 2000;  36 1193-1200
    PubMedGoogle Scholar
  • 27 Loock J, Treichel U, Gerken G, Malago M, Broelsch C E, Phillip T, Heemann U. Treatment of split-liver recipients with poor graft function by albumin dialysis (MARS).  Z Gastroenterol. 2001;  39 (Suppl 2) 18
    PubMedGoogle Scholar
  • 28 Manz T, Ochs A, Bisse E, Strey C, Grotz W. Liver support - a task for nephrologists? Extracorporeal treatment of a patient with fulminant Wilson crisis.  Blood Purif. 2003;  21 232-236
    CrossrefPubMedGoogle Scholar
  • 29 McIntyre C W, Fluck R J, Freeman J G, Lambie S H. Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction.  Clin Nephrol. 2002;  58 376-383
    PubMedGoogle Scholar
  • 30 McIntyre C W, Fluck R J, Freeman J G, Lambie S H. Use of albumin dialysis in the treatment of hepatic and renal dysfunction due to paracetamol intoxication.  Nephrol Dial Transplant. 2002;  17 316-317
    PubMedGoogle Scholar
  • 31 Mitzner S, Stange J. Cell-free artificial liver support: a critical review. In: Körner MM, Körfer R (eds) Current aspects and concepts of nursing, coordinating, bridging and rehabilitation in organ transplantation. Amsterdam; Elsevier 1995: 81-88
    Google Scholar
  • 32 Mitzner S, Stange J, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Henschel J, Schulz M, Lohr M, Liebe S, Schareck W, Hopt U T. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.  Liver Transpl. 2000;  6 277-286
    CrossrefPubMedGoogle Scholar
  • 33 Mitzner S R, Stange J, Klammt S, Peszynski P, Schmidt R. Albumin dialysis using the molecular adsorbent recirculating system.  Curr Opin Nephrol Hypertens. 2001;  10 777-783
    CrossrefPubMedGoogle Scholar
  • 34 Mitzner S, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.  J Amer Soc Nephrol. 2001;  12 (Suppl 17) S75-S82
    PubMedGoogle Scholar
  • 35 Mitzner S, Loock J, Peszynski P, Klammt S, Majcher-Peszynska J, Gramowski A, Stange J, Schmidt R. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS - a review of clinical, biochemical, and electrophysiological data.  Metab Brain Dis. 2002;  17 463-475
    PubMedGoogle Scholar
  • 36 Mullhaupt B, Kullak-Ublick G A, Ambuhl P M, Stocker R, Renner E L. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus.  Hepatol Res. 2003;  25 442-446
    PubMedGoogle Scholar
  • 37 Novelli G, Rossi M, Pretagostini R, Novelli L, Poli L, Ferretti G, Iappelli M, Berloco P, Cortesini R. A 3-year experience with Molecular Adsorbent Recirculating System (MARS): our results on 63 patients with hepatic failure and color doppler US evaluation of cerebral perfusion.  Liver Internat. 2003;  23 (Suppl 3) 10-15
    PubMedGoogle Scholar
  • 38 O'Grady J G, Gimson A E, O'Brien C J, Pucknell A, Hughes R D, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.  Gastroenterology. 1988;  94 1186-1192
    PubMedGoogle Scholar
  • 39 Pares A, Cisneros L, Salmeron J M, Mas A, Torras A, Caballeria J, Rodes J. The Molecular Adsorbent Recirculating System (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis.  J Hepatol. 2002;  36 (Suppl 1) 541
    PubMedGoogle Scholar
  • 40 Parés A, Cisneros L, Salmerón J M, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis.  Amer J Gastroenterol. 2004;  99 1105-1110
    PubMedGoogle Scholar
  • 41 Peszynski P, Klammt S, Peters E, Mitzner S, Stange J, Schmidt R. Albumin dialysis: single pass vs. recirculation (MARS).  Liver. 2002;  22 (Suppl 2) 40-42
    PubMedGoogle Scholar
  • 42 Prokurat S, Grenda R, Lipowski D, Kalicinski P, Migdal M. MARS procedure as a bridge to combined liver-kidney transplantation in severe chromium-copper acute intoxication: a paediatric case report.  Liver. 2002;  22 (Suppl 2) 76-77
    PubMedGoogle Scholar
  • 43 Rifai K, Ernst T, Kretschmer U, Bahr M J, Schneider A, Hafer C, Haller H, Manns M P, Fliser D. Prometheus - a new extracorporeal system for the treatment of liver failure.  J Hepatol. 2003;  39 984-990
    CrossrefPubMedGoogle Scholar
  • 44 Schachschal G, Morgera S, Kupferling S, Schmidt H H, Lochs H. MARS dialysis in the state of chronic rejection in a liver transplant recipient.  Am J Gastroenterol. 2002;  97 1059-1060
    CrossrefPubMedGoogle Scholar
  • 45 Schmidt L E, Svendsen L B, Sorensen V R, Hansen B A, Larsen F S. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure.  Liver Transpl. 2001;  7 709-712
    CrossrefPubMedGoogle Scholar
  • 46 Schmidt L E, Sorensen V R, Svendsen L B, Hansen B A, Larsen F S. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure.  Liver Transpl. 2001;  7 1034-1039
    CrossrefPubMedGoogle Scholar
  • 47 Schmidt L E, Wang L P, Hansen B A, Larsen F S. Systemic hemodynamic effects of treatment with the Molecular Adsorbents Recirculating System in patients with hyperacute liver failure: a prospective, controlled trial.  Liver Transpl. 2003;  9 290-297
    CrossrefPubMedGoogle Scholar
  • 48 Sen S, Felldin M, Steiner C, Larsson B, Gillett G T, Olausson M, Williams R, Jalan R. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease.  Liver Transpl. 2002;  8 962-967
    CrossrefPubMedGoogle Scholar
  • 49 Sen S, Mookerjee R P, Davies N A, Williams R, Jalan R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure.  Aliment Pharmacol Ther. 2002;  16 (Suppl 5) 32-38
    CrossrefPubMedGoogle Scholar
  • 50 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure.  Liver. 2002;  22 (Suppl 2) 5-13
    PubMedGoogle Scholar
  • 51 Sen S, Ratnaraj N, Davies N A, Mookerjee R P, Cooper C E, Patsalos P N, Williams R, Jalan R. Treatment of phenytoin toxicity by the Molecular Adsorbents Recirculating System (MARS).  Epilepsia. 2003;  44 265-267
    CrossrefPubMedGoogle Scholar
  • 52 Sen S, Rose C, Ytrebo L M, Davies N A, Nedredal G I, Drevland S S, Kjonno M, Williams R, Butterworth R, Revhaug A, Jalan R. Albumin dialysis reduces brain water and intracranial pressure in acute liver failure: a randomized controlled study in a pig model (Abstract).  Hepatology. 2003;  34 (Suppl 1) 540A
    PubMedGoogle Scholar
  • 53 Siewert-Delle A, Henriksson B A, Bäckman L. Albumin dialysis with the MARS (Molecular adsorbent Recirculating system) for a patient with acute liver failure due to paracetamol intoxication: a case report. (Abstract).  Z Gastroenterol. 2001;  39 (Suppl 2) 48
    PubMedGoogle Scholar
  • 54 Sorkine P, Ben Abraham R, Szold O. Liver support systems. In: Vincent JL (ed) 2001 Yearbook of intensive care and emergency medicine. Berlin; Springer 2001: 619-627
    Google Scholar
  • 55 Sorkine P, Ben Abraham R, Szold O, Biderman P, Kidron A, Merchav H, Brill S, Oren R. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure.  Crit Care Med. 2001;  29 1332-1336
    PubMedGoogle Scholar
  • 56 Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins.  ASAIO J. 1993;  39 M621-M625
    PubMedGoogle Scholar
  • 57 Stange J, Mitzner S, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Hentschel J, Schulz M, Löhr M, Liebe S, Schareck W, Hopt U T. Liver support by extracorporeal blood purification: a clinical observation.  Liver Transpl. 2000;  6 603-613
    CrossrefPubMedGoogle Scholar
  • 58 Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry.  Liver. 2002;  22 (Suppl 2) 20-25
    PubMedGoogle Scholar
  • 59 Stockmann H B, Hiemstra C A, Marquet R L, Ijzermans J NM. Extracorporeal perfusion for the treatment of acute liver failure.  Ann Surg. 2000;  231 460-470
    CrossrefPubMedGoogle Scholar
  • 60 Voiculescu M, Ioanitescu S, Rusu E, Micu D, Mihaila M, Micu L. Successful application of MARS therapy in a 7 year-old patient with hepatic chronic rejection and severe cholestatic syndrome.  Rom J Gastroenterol. 2002;  11 135-140
    PubMedGoogle Scholar
  • 61 Wehler M, Kokoska J, Reulbach U, Hahn E G, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems.  Hepatology. 2001;  34 255-261
    CrossrefPubMedGoogle Scholar
  • 62 Zakaria N, Wendon J, Creamer D, Heaton N, Devlin J. Albumin dialysis (MARS device) relieves cholestatic pruritus in a dramatic but non-sustained manner.  Hepatology. 2001;  34 550A
    PubMedGoogle Scholar

Dr. med. Steffen Mitzner

Klinik und Poliklinik für Innere Medizin, Universität Rostock

Ernst-Heydemann-Straße 6 · 18055 Rostock

Email: steffen.mitzner@med-uni-rostock.de

      >